BioNTech SE ADR Stock
A loss of -1.880% shows a downward development for BioNTech SE ADR.
Our community is currently high on BioNTech SE ADR with 13 Buy predictions and 3 Sell predictions.
With a target price of 110 € there is a positive potential of 36.05% for BioNTech SE ADR compared to the current price of 80.85 €.
Our community identified positive and negative aspects for BioNTech SE ADR stock for the coming years. 30 users see the criterium "Worthwhile Investment for the next years" as a plus for the BioNTech SE ADR stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.
Pros and Cons of BioNTech SE ADR in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17
Upon initial examination, the financial statements of BioNTech, a company operating within the pharmaceutical industry, present a strong financial position. The company has exhibited consistent growth, maintaining robust liquidity, and profitability ratios.
Asset Growth: BioNTech's total assets increased significantly from €2.31 billion in 2020 to €23.28 billion in 2022, showcasing robust growth within just two years. Particularly, current assets, such as cash and receivables, have exhibited remarkable expansion.
Profitability: The company displays impressive net income figures, from €15.2 million in 2020 to a staggering €9.43 billion in 2022. This increase in net income underscores the company's ability to generate substantial profits.